ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BIAF vs ISPC // FREE CASH FLOW YIELD

bioAffinity Technologies Inc. (NASDAQ) VS. iSpecimen Inc. (NASDAQ) • 15-METRIC TALLY: BIAF 3 — ISPC 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BIAF VS. ISPC) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BIAF ISPC SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 11.20% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) -34.20% -65.00% +30.80 BIAF /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 ISPC /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 35.6 28.9 +6.70 BIAF /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $3.9M $2.0M $1.9M BIAF /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BIAF REV ISPC REV BIAF GROSS % ISPC GROSS % BIAF FCF ISPC FCF
FY 2025 $6.2M $1.9M — 11.2% -$9.4M -$4.2M
FY 2024 $9.4M $9.3M — 45.0% -$7.3M -$8.3M
FY 2023 $2.5M $9.9M — — -$6.0M -$5.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BIAF // BETA —
ISPC // BETA —